Arbutus Biotech (ABUS) heads to a key March Moderna LNP patent trial as imdusiran HBV milestones drive value—get the latest ...
Tourlite Capital Management, an investment management firm, released its third quarter 2024 investor letter, a copy of which can be downloaded here. Tourlite Fund, LP Founder Class returned 4.5% for ...
Arbutus Biopharma Corp. has $191 million cash giving a runway of less than 3 quarters. ABUS stock has been reporting net losses since 2013; in 2022, the net loss per share was $0.12. It maintains low ...
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Arbutus Biopharma (ABUS) is a stock that can certainly grab the ...
Detailed price information for Arbutus Biopharma Corp (ABUS-Q) from The Globe and Mail including charting and trades.
Asianet Newsable on MSN
ABUS stock on track for biggest intraday drop in over 5 years – what’s the issue around its patent in Europe?
The European Patent Office revoked its patent following opposition proceedings brought by affiliates of Moderna and Merck.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results